12:00 AM
Aug 21, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IC485: Began Phase I testing

Icos Corp. (ICOS), Bothell, Wash.
Product: IC485
Business: Autoimmune/Inflammation
Therapeutic category: Receptor antagonist
Target: PDE4
Description: Phosphodiesterase type 4 (PDE4) antagonist

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >